John Henneman Sample Contracts

SEC Documents
Filings
Personal financials
Insider transactions
Previous Companies
officer: CorpVP, Finance & Admin, CFO until August 19th, 2013
Integra Lifesciences Holdings Corp – SECOND AMENDED AND RESTATED 2005 EMPLOYMENT AGREEMENT (May 23rd, 2014)

This Second Amended and Restated 2005 Employment Agreement (this “Agreement”) is made as of the 20th day of May, 2014 by and between Integra LifeSciences Holdings Corporation, a Delaware Corporation (the “Company”) and John B. Henneman, III (“Executive”).

Integra Lifesciences Holdings Corp – News Release (May 1st, 2014)

Plainsboro, New Jersey / May 1, 2014 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the first quarter ending March 31, 2014. Total revenues for the first quarter were $215.1 million, reflecting an increase of $18.4 million over the first quarter of 2013.

Integra Lifesciences Holdings Corp – News Release (February 25th, 2014)
Integra Lifesciences Holdings Corp – News Release (October 28th, 2013)

Plainsboro, New Jersey / October 28, 2013 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the third quarter ending September 30, 2013. Total revenues for the third quarter were $213.2 million, reflecting an increase of $3.2 million over the third quarter of 2012. Currency exchange rates had a negligible effect on revenues.

Integra Lifesciences Holdings Corp – News Release (August 1st, 2013)

Plainsboro, New Jersey, August 1, 2013 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the second quarter ending June 30, 2013. Total revenues for the second quarter were $205.5 million, reflecting a decrease of $4.7 million compared to the second quarter of 2012. Currency exchange rates had a negligible effect on revenues.

Integra Lifesciences Holdings Corp – News Release (May 2nd, 2013)

Plainsboro, New Jersey, May 2, 2013 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the first quarter ending March 31, 2013. Total revenues for the first quarter were $196.7 million, reflecting an increase of $0.5 million over the first quarter of 2012. Currency exchange rates had a negligible effect on revenues.

Integra Lifesciences Holdings Corp – News Release (March 18th, 2013)
Integra Lifesciences Holdings Corp – News Release (February 21st, 2013)
Integra Lifesciences Holdings Corp – News Release (October 24th, 2012)
Integra Lifesciences Holdings Corp – News Release Contacts: Integra LifeSciences Holdings Corporation John B. Henneman, III Investor Relations: Executive Vice President, Finance and Administration, and Chief Financial Officer (609) 275-0500 jack.henneman@integralife.com Angela Steinway (609) 936-2268 angela.steinway@integralife.com (April 25th, 2012)

Plainsboro, New Jersey, April 25, 2012 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the first quarter ending March 31, 2012. Total revenues for the first quarter were $196.2 million, reflecting an increase of $15.1 million, or 8%, over the first quarter of 2011. Excluding the impact of currency exchange rates, revenues increased 9% over the first quarter of 2011. The Company presents revenues by reportable segment and worldwide product category in tables at the end of this press release.

Integra Lifesciences Holdings Corp – RESTRICTED STOCK AGREEMENT (February 27th, 2012)

THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of             ,             (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and John B. Henneman, III, an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant”:

Integra Lifesciences Holdings Corp – News Release (January 5th, 2012)

Plainsboro, New Jersey, January 5, 2012 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced it expects total revenues in the fourth quarter to be approximately $202 million to $203 million. These fourth quarter 2011 revenues are approximately 3% below the low end of previously issued guidance. The revenue shortfall resulted from inventory reduction initiatives by our instruments distributors, weakness outside of the U.S., and weaker than expected sales of our domestic Extremity Reconstruction products.

Integra Lifesciences Holdings Corp – News Release (October 31st, 2011)

Plainsboro, New Jersey, October 31, 2011 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the third quarter ending September 30, 2011. Total revenues for the third quarter were $202.2 million, reflecting an increase of $15.6 million, or 8%, over the third quarter of 2010. Excluding the impact of currency exchange rates, revenues increased 7% over the third quarter of 2010. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (September 26th, 2011)

PLAINSBORO, NJ, September 26, 2011 (GlobeNewswire) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the closing of its previously announced acquisition of Ascension Orthopedics, Inc. (“Ascension.”) Ascension, based in Austin, Texas, develops and distributes a complementary range of implants for the shoulder, elbow, wrist, hand, foot and ankle.

Integra Lifesciences Holdings Corp – Integra LifeSciences Announces Agreement to Acquire Ascension Orthopedics Integra Extremity Reconstruction to Expand in Foot, Hand and Shoulder Markets Company to Gain Access to PyroCarbon Technology (September 12th, 2011)

PLAINSBORO, NJ and AUSTIN, TX, September 12, 2011 (GlobeNewswire) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Ascension Orthopedics, Inc. (“Ascension”) today announced an agreement for Integra to acquire Ascension, a provider of high quality, innovative products for the foot, hand and shoulder markets, for approximately $65 million in cash, subject to adjustments. When combined with Integra’s legacy business, the products will represent approximately 45% of Integra’s Orthopedics revenues.

Integra Lifesciences Holdings Corp – News Release (July 28th, 2011)

Plainsboro, New Jersey, July 28, 2011 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the second quarter ending June 30, 2011. Total revenues for the second quarter were $193.3 million, reflecting an increase of $14.7 million, or 8%, over the second quarter of 2010. Excluding the impact of currency exchange rates, revenues increased 6% over the second quarter of 2010. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (June 8th, 2011)

PLAINSBORO, N.J., June [8], 2011 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has established new terms under its credit facility, including lower pricing and an extended maturity date, with its bank group led by Bank of America, N.A and JPMorgan Chase Bank.

Integra Lifesciences Holdings Corp – News Release (May 24th, 2011)

PLAINSBORO, N.J., May 24, 2011 (GlobeNewswire) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has acquired SeaSpine, Inc., a provider of high quality, innovative products for the spine fusion market, for $89 million in cash, subject to certain post-closing adjustments. After the combination, the spine and orthobiologics portfolio is now the largest component of Integra’s Orthopedics revenue category.

Integra Lifesciences Holdings Corp – News Release (April 28th, 2011)

Plainsboro, New Jersey, April 28, 2011 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the first quarter ending March 31, 2011. Total revenues for the first quarter were $181.0 million, reflecting an increase of $8.3 million, or 5%, over the first quarter of 2010. Excluding the impact of currency exchange rates, revenues increased 4.4% over the first quarter of 2010. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (February 24th, 2011)

Plainsboro, New Jersey, February 24, 2011 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the fourth quarter and full year ending December 31, 2010. Total revenues for the fourth quarter were $194.1 million, reflecting an increase of $10.6 million, or 6%, over the fourth quarter of 2009. Total revenues in the full year of 2010 were $732.1 million, reflecting an increase of $49.6 million, or 7%, over the full year of 2009. Excluding the impact of currency exchange rates, revenues increased 7% over the fourth quarter of 2009 and 7% over the full year 2009. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (October 28th, 2010)

Plainsboro, New Jersey, October 28, 2010 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its financial results for the third quarter ending September 30, 2010. Total revenues for the third quarter were $186.6 million, reflecting an increase of $14.4 million, or 8.3%, over the third quarter of 2009. Excluding the impact of changes in foreign currency exchange rates, revenues grew 9%. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – RESTRICTED STOCK AGREEMENT (October 12th, 2010)

THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of December 15, 2010 (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and John B. Henneman, III, an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant”:

Integra Lifesciences Holdings Corp – Gerard S. Carlozzi to retire at end of 2010 John B. Henneman, III extends employment agreement through 2012 (October 12th, 2010)

Plainsboro, New Jersey, October 12, 2010 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) Stuart Essig, Integra’s Chief Executive Officer, announced today the appointment of Peter J. Arduini to the position of President and Chief Operating Officer, effective November 1, 2010. In this position, Mr. Arduini will have direct responsibility for all the Company’s operations, including Orthopedics, Neurosurgery and Instruments. He will report to Mr. Essig, Integra’s Chief Executive Officer. Mr. Arduini will succeed Mr. Gerard S. Carlozzi, who is planning to retire at the end of 2010.

Integra Lifesciences Holdings Corp – AMENDMENT 2010-1 TO THE AMENDED AND RESTATED 2005 EMPLOYMENT AGREEMENT (October 12th, 2010)

THIS AMENDMENT, dated as of October 12, 2010, between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”) and John B. Henneman, III (“Executive”).

Integra Lifesciences Holdings Corp – News Release (July 29th, 2010)

Plainsboro, New Jersey, July 29, 2010 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the second quarter ending June 30, 2010. Total revenues for the second quarter were $178.6 million, reflecting an increase of $12.9 million, or 8%, over the second quarter of 2009. We present revenues by product category in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (May 3rd, 2010)

Plainsboro, New Jersey, May 3, 2010 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the first quarter ending March 31, 2010. Total revenues for the first quarter were $172.7 million, reflecting an increase of $11.7 million, or 7%, over the first quarter of 2009. Excluding the impact of currency exchange rates, revenues increased 6% over the first quarter of 2009. Revenues by product category are presented in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (March 1st, 2010)

Plainsboro, New Jersey, March 1, 2010 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the fourth quarter and full year ending December 31, 2009. Total revenues for the fourth quarter were $183.5 million, reflecting an increase of $9.2 million, or 5%, over the fourth quarter of 2008. Total revenues in the full year of 2009 were $682.5 million, reflecting an increase of $27.9 million, or 4%, over the full year of 2008. Excluding the impact of currency exchange rates, revenues increased 3% over the fourth quarter of 2008 and 5% over the full year 2008. Revenues by product category are presented in a table at the end of this press release.

Integra Lifesciences Holdings Corp – News Release (November 4th, 2009)

Plainsboro, New Jersey, November 4, 2009 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the third quarter ending September 30, 2009. Total revenues were $172.3 million, reflecting an increase of $5.3 million, or 3%, over the third quarter of 2008. Excluding the impact of currency exchange rates, revenues increased 4%. Revenues by product category are presented in a table at the end of this press release.

Integra Lifesciences Holdings Corp – AMENDMENT 2009-1 TO THE AMENDED AND RESTATED 2005 EMPLOYMENT AGREEMENT (April 13th, 2009)

THIS AMENDMENT, dated as of April 13, 2009, between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”) and John B. Henneman, III (“Executive”).

Integra Lifesciences Holdings Corp – News Release Contacts: Integra LifeSciences Holdings Corporation (January 9th, 2009)

Plainsboro, New Jersey, January 9, 2009 – Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that its 2008 and 2009 revenues and GAAP and adjusted diluted earnings per share results are expected to be below the guidance previously provided and that it has acquired Minnesota Scientific, Inc. (d/b/a Omni-Tract Surgical).

Integra Lifesciences Holdings Corp – AMENDMENT 2008-2 TO THE AMENDED AND RESTATED 2005 EMPLOYMENT AGREEMENT (December 24th, 2008)

THIS AMENDMENT, dated as of December 18, 2008, between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”) and John B. Henneman, III (“Executive”).

Integra Lifesciences Holdings Corp – INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONTRACT STOCK / RESTRICTED UNITS AGREEMENT Pursuant to 2003 EQUITY INCENTIVE PLAN (December 24th, 2008)

AGREEMENT, dated as of December 18, 2008, by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [                         ] (“Executive”).

Integra Lifesciences Holdings Corp – News Release Contacts: Integra LifeSciences Holdings Corporation (July 24th, 2008)

Plainsboro, New Jersey / July 24, 2008 — Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that it has agreed to acquire Theken Spine, LLC, Theken Disc, LLC and Therics, LLC (together “Theken”) for $75 million in cash at closing, subject to certain adjustments, and up to $125 million in future payments based on the performance of the business after closing. The future payments will be tied to revenues of the business in the two years after closing. The acquisition is expected to be completed in the third calendar quarter of 2008.

Integra Lifesciences Holdings Corp – STOCK OPTION GRANT AND AGREEMENT (June 6th, 2008)
Integra Lifesciences Holdings Corp – News Release (June 6th, 2008)